{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:13Z","timestamp":1790902453578,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00105-026-05776-1","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:39:52Z","timestamp":1790084392000},"page":"690-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Therapien bei blasenbildenden Autoimmunerkrankungen","New treatment options for autoimmune bullous diseases"],"prefix":"10.1007","volume":"77","author":[{"given":"Nina","family":"van Beek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"10201","key":"5776_CR1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","volume":"394","author":"E Schmidt","year":"2019","unstructured":"Schmidt\u00a0E, Kasperkiewicz\u00a0M, Joly\u00a0P (2019) Pemphigus. Lancet 394(10201):882\u2013894","journal-title":"Lancet"},{"issue":"9863","key":"5776_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt\u00a0E, Zillikens\u00a0D (2013) Pemphigoid diseases. Lancet 381(9863):320\u2013332","journal-title":"Lancet"},{"issue":"1","key":"5776_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00595-5","volume":"11","author":"H Akbarialiabad","year":"2025","unstructured":"Akbarialiabad\u00a0H, Schmidt\u00a0E, Patsatsi\u00a0A, Lim\u00a0YL, Mosam\u00a0A, Tasanen\u00a0K et\u00a0al (2025) Bullous pemphigoid. Nature reviews Disease primers 11(1):12","journal-title":"Nature reviews Disease primers"},{"key":"5776_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"M Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz\u00a0M, Ellebrecht\u00a0CT, Takahashi\u00a0H, Yamagami\u00a0J, Zillikens\u00a0D, Payne\u00a0AS et\u00a0al (2017) Pemphigus. Nature reviews Disease primers 3:17026","journal-title":"Nature reviews Disease primers"},{"issue":"4","key":"5776_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-026-02292-3","volume":"86","author":"M Kasperkiewicz","year":"2026","unstructured":"Kasperkiewicz\u00a0M, van Beek\u00a0N, Schmidt\u00a0E (2026) Autoimmune Bullous Diseases: Therapeutic Update. Drugs 86(4):485\u2013506","journal-title":"Drugs"},{"issue":"1","key":"5776_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100004","volume":"1","author":"K Kridin","year":"2021","unstructured":"Kridin\u00a0K, Schmidt\u00a0E (2021) Epidemiology of Pemphigus. JID Innov 1(1):100004","journal-title":"JID Innov"},{"issue":"4","key":"5776_CR7","first-page":"405","volume":"21","author":"MM Holtsche","year":"2023","unstructured":"Holtsche\u00a0MM, Boch\u00a0K, Schmidt\u00a0E (2023) Autoimmune bullous dermatoses. J\u00a0Dtsch Dermatol Ges 21(4):405\u2013412","journal-title":"J Dtsch Dermatol Ges"},{"issue":"24","key":"5776_CR8","first-page":"413","volume":"118","author":"NV Beek","year":"2021","unstructured":"Beek\u00a0NV, Zillikens\u00a0D, Schmidt\u00a0E (2021) Bullous Autoimmune Dermatoses-Clinical Features, Diagnostic Evaluation, and Treatment Options. Dtsch Arztebl Int 118(24):413\u2013420","journal-title":"Dtsch Arztebl Int"},{"key":"5776_CR9","doi-asserted-by":"crossref","unstructured":"Joly P, Horwath B, Patsatsi A, Uzun S, Bech R, Beissert S, et\u00a0al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J\u00a0Eur Acad Dermatol Venereol. 2020 Aug\u00a024.","DOI":"10.1111\/jdv.16752"},{"issue":"6","key":"5776_CR10","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/jdv.18931","volume":"37","author":"E Antiga","year":"2023","unstructured":"Antiga\u00a0E, Bech\u00a0R, Maglie\u00a0R, Genovese\u00a0G, Borradori\u00a0L, Bockle\u00a0B et\u00a0al (2023) S2k guidelines on the management of paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J\u00a0Eur Acad Dermatol Venereol 37(6):1118\u20131134","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5776_CR11","unstructured":"S2k-Leitlinie \u201eDiagnostik und Therapie des Pemphigus vulgaris\/foliaceus und des bull\u00f6sen Pemphigoids\u201c AWMF-Reg.-Nr.\u00a0013\u2013071"},{"issue":"5","key":"5776_CR12","first-page":"516","volume":"18","author":"E Schmidt","year":"2020","unstructured":"Schmidt\u00a0E, Sticherling\u00a0M, Sardy\u00a0M, Eming\u00a0R, Goebeler\u00a0M, Hertl\u00a0M et\u00a0al (2020) S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update. J\u00a0Dtsch Dermatol Ges 18(5):516\u2013526","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"5776_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/bjd\/ljad489","volume":"190","author":"N van Beek","year":"2024","unstructured":"van Beek\u00a0N, Eming\u00a0R, Reuss\u00a0A, Zillikens\u00a0D, Sardy\u00a0M, Gunther\u00a0C et\u00a0al (2024) Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial. Br J Dermatol 190(5):657\u2013667","journal-title":"Br J Dermatol"},{"key":"5776_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","volume":"64","author":"Y Zhang","year":"2022","unstructured":"Zhang\u00a0Y, Tian\u00a0J, Xiao\u00a0F, Zheng\u00a0L, Zhu\u00a0X, Wu\u00a0L et\u00a0al (2022) B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine Growth Factor Rev 64:57\u201370","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"5776_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik\u00a0M, Kozicky\u00a0LK, Gandhi\u00a0AK, Blumberg\u00a0RS (2023) The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 23(7):415\u2013432","journal-title":"Nat Rev Immunol"},{"key":"5776_CR16","unstructured":"Joly P MD, Aoyama Y, Caux F, De D, Flouri M, Goebeler M, Ji C, Kiritsi D, Pan M, Patsatsi A, Schmidt E, Vassileva S, Stoykov I, Verheesen P, Werth VP, Hall RP and the ADDRESS Investigator Study Group. Efficacy and safety of subcutaneous efgartigimod in moderate to severe pemphigus (ADDRESS): A\u00a0phase\u00a03, randomized, double-blind trial. . Br J Dermatol. in preparation."},{"issue":"7","key":"5776_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard\u00a0JF Jr, Bril\u00a0V, Vu\u00a0T, Karam\u00a0C, Peric\u00a0S, Margania\u00a0T et\u00a0al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536","journal-title":"Lancet Neurol"},{"issue":"3","key":"5776_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler\u00a0M, Bata-Csorgo\u00a0Z, De Simone\u00a0C, Didona\u00a0B, Remenyik\u00a0E, Reznichenko\u00a0N et\u00a0al (2022) Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a\u00a0neonatal Fc receptor inhibitor: a\u00a0phase\u00a0II multicentre, open-label feasibility trial. Br J Dermatol 186(3):429\u2013439","journal-title":"Br J Dermatol"},{"key":"5776_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863095","volume":"13","author":"M Maho-Vaillant","year":"2022","unstructured":"Maho-Vaillant\u00a0M, Sips\u00a0M, Golinski\u00a0ML, Vidarsson\u00a0G, Goebeler\u00a0M, Stoevesandt\u00a0J et\u00a0al (2022) FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. Front Immunol 13:863095","journal-title":"Front Immunol"},{"issue":"6295","key":"5776_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht\u00a0CT, Bhoj\u00a0VG, Nace\u00a0A, Choi\u00a0EJ, Mao\u00a0X, Cho\u00a0MJ et\u00a0al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353(6295):179\u2013184","journal-title":"Science"},{"issue":"15","key":"5776_CR21","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMcibr1608900","volume":"375","author":"M Amagai","year":"2016","unstructured":"Amagai\u00a0M (2016) Modulating Immunity to Treat Autoimmune Disease. N Engl J Med 375(15):1487\u20131489","journal-title":"N Engl J Med"},{"issue":"17","key":"5776_CR22","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1182\/blood.2024025413","volume":"145","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos\u00a0D, Meyer\u00a0EH, Schett\u00a0G (2025) CAR T\u00a0cells in autoimmunity: game changer or stepping stone? Blood 145(17):1841\u20131849","journal-title":"Blood"},{"issue":"2","key":"5776_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100339","volume":"5","author":"M Karakioulaki","year":"2025","unstructured":"Karakioulaki\u00a0M, Dunn\u00a0P, Murrell\u00a0DF, Payne\u00a0A, Schmidt\u00a0E, Werth\u00a0V et\u00a0al (2025) Advances in Pemphigus and Pemphigoid: A\u00a0Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece. JID Innov 5(2):100339","journal-title":"JID Innov"},{"key":"5776_CR24","doi-asserted-by":"crossref","unstructured":"Didona D, Hudemann C, Garn H, Krzikalla D, Wang SH, Hinterseher J, et\u00a0al. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3\u2011peptide-coupled tolerizing nanoparticles in pemphigus. Br J Dermatol. 2025 Aug\u00a07.","DOI":"10.1093\/bjd\/ljaf311"},{"key":"5776_CR25","doi-asserted-by":"crossref","unstructured":"Rujitharanawong C, Payne AS. Immunoregulatory effects of TPM203 peptide-nanoparticle therapy in pemphigus vulgaris. Br J Dermatol. 2025 Aug\u00a021.","DOI":"10.1093\/bjd\/ljaf323"},{"issue":"4","key":"5776_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1515\/rir-2024-0029","volume":"5","author":"H Huang","year":"2024","unstructured":"Huang\u00a0H, Wei\u00a0X (2024) Therapeutic potential of CD20\/CD3 bispecific antibodies in the treatment of autoimmune diseases. Rheumatol Immunol Res 5(4):209\u2013216","journal-title":"Rheumatol Immunol Res"},{"issue":"9","key":"5776_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander\u00a0T, Kronke\u00a0J, Cheng\u00a0Q, Keller\u00a0U, Kronke\u00a0G (2024) Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus. N Engl J Med 391(9):864\u2013866","journal-title":"N Engl J Med"},{"issue":"1","key":"5776_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35741-0","volume":"14","author":"AM Sigmund","year":"2023","unstructured":"Sigmund\u00a0AM, Winkler\u00a0M, Engelmayer\u00a0S, Kugelmann\u00a0D, Egu\u00a0DT, Steinert\u00a0LS et\u00a0al (2023) Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus. Nat Commun 14(1):116","journal-title":"Nat Commun"},{"key":"5776_CR29","doi-asserted-by":"crossref","unstructured":"Sigmund AM, Bayerbach FC, Kugelmann D, Butz E, Moztarzadeh S, Schikora ME, et\u00a0al. Epac1 contributes to apremilast-mediated rescue of pemphigus autoantibody-induced loss of keratinocyte adhesion. JCI insight. 2025 May\u00a022;10(10).","DOI":"10.1172\/jci.insight.187481"},{"key":"5776_CR30","doi-asserted-by":"crossref","unstructured":"Alhasawi RH, Shaheen EA, Alshabanat NM, Brashi R, Ahmed WA, Alqahtani SH, et\u00a0al. The efficacy of apremilast in pemphigus: a\u00a0systematic review of case reports. Dermatol Reports. 2025 May\u00a07.","DOI":"10.4081\/dr.2025.10245"},{"issue":"2","key":"5776_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","volume":"46","author":"L Chikhoune","year":"2025","unstructured":"Chikhoune\u00a0L, Poggi\u00a0C, Moreau\u00a0J, Dubucquoi\u00a0S, Hachulla\u00a0E, Collet\u00a0A et\u00a0al (2025) JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases. Rev Med Interne 46(2):89\u2013106","journal-title":"Rev Med Interne"},{"key":"5776_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563286","volume":"16","author":"X Lin","year":"2025","unstructured":"Lin\u00a0X, Li\u00a0X, Zhai\u00a0Z, Zhang\u00a0M (2025) JAK-STAT pathway, type\u00a0I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid. Front Immunol 16:1563286","journal-title":"Front Immunol"},{"issue":"12","key":"5776_CR33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/14740338.2023.2248872","volume":"22","author":"L Wang","year":"2023","unstructured":"Wang\u00a0L, Zhao\u00a0B (2023) Janus kinase inhibitor-Tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data. Expert Opin Drug Saf 22(12):1317\u20131320","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"5776_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12026-020-09122-y","volume":"68","author":"K Juczynska","year":"2020","unstructured":"Juczynska\u00a0K, Wozniacka\u00a0A, Waszczykowska\u00a0E, Danilewicz\u00a0M, Wagrowska-Danilewicz\u00a0M, Zebrowska\u00a0A (2020) Expression of JAK 3, STAT2, STAT4, and STAT6 in pemphigus vulgaris. Immunol Res 68(2):97\u2013103","journal-title":"Immunol Res"},{"issue":"12","key":"5776_CR35","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1007\/s12325-024-02992-w","volume":"41","author":"VP Werth","year":"2024","unstructured":"Werth\u00a0VP, Murrell\u00a0DF, Joly\u00a0P, Heck\u00a0R, Orengo\u00a0JM, Ardeleanu\u00a0M et\u00a0al (2024) Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review). Advances in therapy 41(12):4418\u20134432","journal-title":"Advances in therapy"},{"key":"5776_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128154","volume":"10","author":"R Maglie","year":"2023","unstructured":"Maglie\u00a0R, Solimani\u00a0F, Didona\u00a0D, Pipito\u00a0C, Antiga\u00a0E, Di Zenzo\u00a0G (2023) The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets. Front Med (Lausanne) 10:1128154","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"5776_CR37","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","volume":"132","author":"P Joly","year":"2012","unstructured":"Joly\u00a0P, Baricault\u00a0S, Sparsa\u00a0A, Bernard\u00a0P, Bedane\u00a0C, Duvert-Lehembre\u00a0S et\u00a0al (2012) Incidence and mortality of bullous pemphigoid in France. J\u00a0Invest Dermatol 132(8):1998\u20132004","journal-title":"J Invest Dermatol"},{"issue":"5","key":"5776_CR38","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/jdv.17107","volume":"35","author":"N van Beek","year":"2021","unstructured":"van Beek\u00a0N, Weidinger\u00a0A, Schneider\u00a0SW, Kleinheinz\u00a0A, Glaser\u00a0R, Holtsche\u00a0MM et\u00a0al (2021) Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. J\u00a0Eur Acad Dermatol Venereol 35(5):1197\u20131202","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"5776_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","volume":"71","author":"KE Brick","year":"2014","unstructured":"Brick\u00a0KE, Weaver\u00a0CH, Lohse\u00a0CM, Pittelkow\u00a0MR, Lehman\u00a0JS, Camilleri\u00a0MJ et\u00a0al (2014) Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J\u00a0Am Acad Dermatol 71(1):92\u201399","journal-title":"J Am Acad Dermatol"},{"key":"5776_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363032","volume":"15","author":"N van Beek","year":"2024","unstructured":"van Beek\u00a0N, Holtsche\u00a0MM, Atefi\u00a0I, Olbrich\u00a0H, Schmitz\u00a0MJ, Pruessmann\u00a0J et\u00a0al (2024) State-of-the-art diagnosis of autoimmune blistering diseases. Front Immunol 15:1363032","journal-title":"Front Immunol"},{"issue":"10","key":"5776_CR41","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori\u00a0L, Van Beek\u00a0N, Feliciani\u00a0C, Tedbirt\u00a0B, Antiga\u00a0E, Bergman\u00a0R et\u00a0al (2022) Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J\u00a0Eur Acad Dermatol Venereol 36(10):1689\u20131704","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"5776_CR42","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/jdv.17397","volume":"35","author":"H Rashid","year":"2021","unstructured":"Rashid\u00a0H, Lamberts\u00a0A, Borradori\u00a0L, Alberti-Violetti\u00a0S, Barry\u00a0RJ, Caproni\u00a0M et\u00a0al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part\u00a0I. J\u00a0Eur Acad Dermatol Venereol 35(9):1750\u20131764","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"5776_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103036","volume":"21","author":"G Du","year":"2022","unstructured":"Du\u00a0G, Patzelt\u00a0S, van Beek\u00a0N, Schmidt\u00a0E (2022) Mucous membrane pemphigoid. Autoimmun Rev 21(4):103036","journal-title":"Autoimmun Rev"},{"key":"5776_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00034","volume":"10","author":"M Kamaguchi","year":"2019","unstructured":"Kamaguchi\u00a0M, Iwata\u00a0H (2019) The Diagnosis and Blistering Mechanisms of Mucous Membrane Pemphigoid. Front Immunol 10:34","journal-title":"Front Immunol"},{"issue":"5","key":"5776_CR45","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling\u00a0M, Franke\u00a0A, Aberer\u00a0E, Glaser\u00a0R, Hertl\u00a0M, Pfeiffer\u00a0C et\u00a0al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177(5):1299\u20131305","journal-title":"Br J Dermatol"},{"issue":"10079","key":"5776_CR46","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams\u00a0HC, Wojnarowska\u00a0F, Kirtschig\u00a0G, Mason\u00a0J, Godec\u00a0TR, Schmidt\u00a0E et\u00a0al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389(10079):1630\u20131638","journal-title":"Lancet"},{"issue":"9","key":"5776_CR47","first-page":"1109","volume":"16","author":"F Hubner","year":"2018","unstructured":"Hubner\u00a0F, Kasperkiewicz\u00a0M, Knuth-Rehr\u00a0D, Shimanovich\u00a0I, Hubner\u00a0J, Sufke\u00a0S et\u00a0al (2018) Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption. J\u00a0Dtsch Dermatol Ges 16(9):1109\u20131118","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"5776_CR48","first-page":"1530","volume":"20","author":"SC Hofmann","year":"2022","unstructured":"Hofmann\u00a0SC, Gunther\u00a0C, Bockle\u00a0BC, Didona\u00a0D, Ehrchen\u00a0J, Gaskins\u00a0M et\u00a0al (2022) S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. J\u00a0Dtsch Dermatol Ges 20(11):1530\u20131550","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"5776_CR49","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jdv.17395","volume":"35","author":"E Schmidt","year":"2021","unstructured":"Schmidt\u00a0E, Rashid\u00a0H, Marzano\u00a0AV, Lamberts\u00a0A, Di Zenzo\u00a0G, Diercks\u00a0GFH et\u00a0al (2021) European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J\u00a0Eur Acad Dermatol Venereol 35(10):1926\u20131948","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"5776_CR50","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","volume":"41","author":"DF Murrell","year":"2024","unstructured":"Murrell\u00a0DF, Joly\u00a0P, Werth\u00a0VP, Ujiie\u00a0H, Worm\u00a0M, Mangold\u00a0AR et\u00a0al (2024) Study Design of a Phase 2\/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT. Advances in therapy 41(7):2991\u20133002","journal-title":"Advances in therapy"},{"issue":"3","key":"5776_CR51","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","volume":"75","author":"D Simon","year":"2020","unstructured":"Simon\u00a0D, Yousefi\u00a0S, Cazzaniga\u00a0S, Burgler\u00a0C, Radonjic\u00a0S, Houriet\u00a0C et\u00a0al (2020) Mepolizumab failed to affect bullous pemphigoid: A\u00a0randomized, placebo-controlled, double-blind phase\u00a02 pilot study. Allergy 75(3):669\u2013672","journal-title":"Allergy"},{"issue":"2","key":"5776_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/bjd\/ljad369","volume":"190","author":"R Chebani","year":"2024","unstructured":"Chebani\u00a0R, Lombart\u00a0F, Chaby\u00a0G, Dadban\u00a0A, Debarbieux\u00a0S, Viguier\u00a0MA et\u00a0al (2024) Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a\u00a0French national multicentre retrospective study of 100 patients. Br J Dermatol 190(2):258\u2013265","journal-title":"Br J Dermatol"},{"issue":"2","key":"5776_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","volume":"25","author":"M Karakioulaki","year":"2024","unstructured":"Karakioulaki\u00a0M, Eyerich\u00a0K, Patsatsi\u00a0A (2024) Advancements in Bullous Pemphigoid Treatment: A\u00a0Comprehensive Pipeline Update. Am J Clin Dermatol 25(2):195\u2013212","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"5776_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100307","volume":"4","author":"T Passeron","year":"2024","unstructured":"Passeron\u00a0T, Fontas\u00a0E, Boye\u00a0T, Richard\u00a0MA, Delaporte\u00a0E, Dereure\u00a0O (2024) Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study. JID Innov 4(6):100307","journal-title":"JID Innov"},{"issue":"6","key":"5776_CR55","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","volume":"158","author":"CD Sadik","year":"2022","unstructured":"Sadik\u00a0CD, Rashid\u00a0H, Hammers\u00a0CM, Diercks\u00a0GFH, Weidinger\u00a0A, Beissert\u00a0S et\u00a0al (2022) Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol 158(6):641\u2013649","journal-title":"JAMA Dermatol"},{"issue":"12","key":"5776_CR56","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jid.2019.04.025","volume":"139","author":"PC Freire","year":"2019","unstructured":"Freire\u00a0PC, Munoz\u00a0CH, Derhaschnig\u00a0U, Schoergenhofer\u00a0C, Firbas\u00a0C, Parry\u00a0GC et\u00a0al (2019) Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid. J\u00a0Invest Dermatol 139(12):2417\u20132424 (e2)","journal-title":"J Invest Dermatol"},{"issue":"8","key":"5776_CR57","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.jid.2017.03.037","volume":"137","author":"EN Heppe","year":"2017","unstructured":"Heppe\u00a0EN, Tofern\u00a0S, Schulze\u00a0FS, Ishiko\u00a0A, Shimizu\u00a0A, Sina\u00a0C et\u00a0al (2017) Experimental Laminin 332 Mucous Membrane Pemphigoid Critically Involves C5aR1 and Reflects Clinical and Immunopathological Characteristics of the Human Disease. J\u00a0Invest Dermatol 137(8):1709\u20131718","journal-title":"J Invest Dermatol"},{"issue":"12","key":"5776_CR58","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","volume":"136","author":"S Sarny","year":"2018","unstructured":"Sarny\u00a0S, Hucke\u00a0M, El-Shabrawi\u00a0Y (2018) Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib. JAMA Ophthalmol 136(12):1420\u20131422","journal-title":"JAMA Ophthalmol"},{"key":"5776_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdcr.2022.07.013","volume":"27","author":"KM Burningham","year":"2022","unstructured":"Burningham\u00a0KM, Cao\u00a0J, Dominguez\u00a0AR (2022) Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate. JAAD Case Rep 27:67\u201369","journal-title":"JAAD Case Rep"},{"issue":"4","key":"5776_CR60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson\u00a0EL, Silverberg\u00a0JI, Nosbaum\u00a0A, Winthrop\u00a0K, Guttman-Yassky\u00a0E, Hoffmeister\u00a0KM et\u00a0al (2024) Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure. Am J Clin Dermatol 25(4):639\u2013654","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"5776_CR61","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jaad.2024.08.033","volume":"91","author":"R Xue","year":"2024","unstructured":"Xue\u00a0R, Li\u00a0G, Zhou\u00a0Y, Wang\u00a0B, Xu\u00a0Y, Zhao\u00a0P et\u00a0al (2024) Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial. J\u00a0Am Acad Dermatol 91(6):1113\u20131117","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"5776_CR62","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00403-012-1213-9","volume":"304","author":"P Quaglino","year":"2012","unstructured":"Quaglino\u00a0P, Antiga\u00a0E, Comessatti\u00a0A, Caproni\u00a0M, Nardo\u00a0T, Ponti\u00a0R et\u00a0al (2012) Circulating CD4+ CD25brightFOXP3+ regulatory T\u2011cells are significantly reduced in bullous pemphigoid patients. Arch Dermatol Res 304(8):639\u2013645","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"5776_CR63","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","volume":"142","author":"K Muramatsu","year":"2018","unstructured":"Muramatsu\u00a0K, Ujiie\u00a0H, Kobayashi\u00a0I, Nishie\u00a0W, Izumi\u00a0K, Ito\u00a0T et\u00a0al (2018) Regulatory T\u2011cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects. J\u00a0Allergy Clin Immunol 142(6):1818\u20131830 (e6)","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"5776_CR64","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/ced.13135","volume":"42","author":"T Gambichler","year":"2017","unstructured":"Gambichler\u00a0T, Tsitlakidon\u00a0A, Skrygan\u00a0M, Hoxtermann\u00a0S, Susok\u00a0L, Hessam\u00a0S (2017) T regulatory cells and other lymphocyte subsets in patients with bullous pemphigoid. Clin Exp Dermatol 42(6):632\u2013637","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"5776_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50283-3","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu\u00a0T, Wang\u00a0Z, Xue\u00a0X, Wang\u00a0Z, Zhang\u00a0Y, Mi\u00a0Z et\u00a0al (2024) Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease. Nat Commun 15(1):5949","journal-title":"Nat Commun"},{"issue":"2","key":"5776_CR66","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ced\/llad331","volume":"49","author":"R Maglie","year":"2024","unstructured":"Maglie\u00a0R, Baffa\u00a0ME, Senatore\u00a0S, Pipito\u00a0C, Caproni\u00a0M, Solimani\u00a0F et\u00a0al (2024) Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease. Clin Exp Dermatol 49(2):161\u2013163","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"5776_CR67","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/bjd\/ljaf035","volume":"192","author":"R Maglie","year":"2025","unstructured":"Maglie\u00a0R, Didona\u00a0D, Solimani\u00a0F, Pipito\u00a0C, Baffa\u00a0ME, Hertl\u00a0M et\u00a0al (2025) Off-label use of tralokinumab in the treatment of bullous pemphigoid: a\u00a0case series. Br J Dermatol 192(6):1124\u20131126","journal-title":"Br J Dermatol"},{"key":"5776_CR68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","volume":"96","author":"L Chakievska","year":"2019","unstructured":"Chakievska\u00a0L, Holtsche\u00a0MM, Kunstner\u00a0A, Goletz\u00a0S, Petersen\u00a0BS, Thaci\u00a0D et\u00a0al (2019) IL-17A is functionally relevant and a\u00a0potential therapeutic target in bullous pemphigoid. J\u00a0Autoimmun 96:104\u2013112","journal-title":"J Autoimmun"},{"issue":"5","key":"5776_CR69","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","volume":"18","author":"EH Kowalski","year":"2019","unstructured":"Kowalski\u00a0EH, Kneibner\u00a0D, Kridin\u00a0K, Amber\u00a0KT (2019) Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev 18(5):526\u2013534","journal-title":"Autoimmun Rev"},{"issue":"12","key":"5776_CR70","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","volume":"134","author":"S Le Jan","year":"2014","unstructured":"Le Jan\u00a0S, Plee\u00a0J, Vallerand\u00a0D, Dupont\u00a0A, Delanez\u00a0E, Durlach\u00a0A et\u00a0al (2014) Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J\u00a0Invest Dermatol 134(12):2908\u20132917","journal-title":"J Invest Dermatol"},{"issue":"8","key":"5776_CR71","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","volume":"98","author":"U Rudrich","year":"2018","unstructured":"Rudrich\u00a0U, Gehring\u00a0M, Papakonstantinou\u00a0E, Illerhaus\u00a0A, Engmann\u00a0J, Kapp\u00a0A et\u00a0al (2018) Eosinophils are a\u00a0Major Source of Interleukin-31 in Bullous Pemphigoid. Acta Derm Venereol 98(8):766\u2013771","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"5776_CR72","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jdermsci.2017.04.008","volume":"87","author":"D Bonciani","year":"2017","unstructured":"Bonciani\u00a0D, Quintarelli\u00a0L, Del Bianco\u00a0E, Bianchi\u00a0B, Caproni\u00a0M (2017) Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid. J\u00a0Dermatol Sci 87(2):210\u2013212","journal-title":"J Dermatol Sci"},{"issue":"3","key":"5776_CR73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jdermsci.2017.07.019","volume":"87","author":"M Salz","year":"2017","unstructured":"Salz\u00a0M, Haeberle\u00a0S, Hoffmann\u00a0J, Enk\u00a0AH, Hadaschik\u00a0EN (2017) Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE. J\u00a0Dermatol Sci 87(3):309\u2013311","journal-title":"J Dermatol Sci"},{"issue":"1","key":"5776_CR74","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-04052-x","volume":"317","author":"N Heidari","year":"2025","unstructured":"Heidari\u00a0N, Hosseini\u00a0S, Heidari\u00a0A, Ghane\u00a0Y, Daneshpazhooh\u00a0M, Mahmoudi\u00a0H (2025) A systematic review of the role of interleukin-17 inhibitors in bullous pemphigoid: therapeutic and paradoxical effects. Arch Dermatol Res 317(1):544","journal-title":"Arch Dermatol Res"},{"issue":"12","key":"5776_CR75","first-page":"1478","volume":"18","author":"MM Holtsche","year":"2020","unstructured":"Holtsche\u00a0MM, Hammers\u00a0CM, Chakievska\u00a0L, Ludwig\u00a0RJ, Thaci\u00a0D, Zillikens\u00a0D et\u00a0al (2020) Adjuvant treatment with secukinumab induced long term remission in a\u00a0patient with severe bullous pemphigoid. J\u00a0Dtsch Dermatol Ges 18(12):1478\u20131480","journal-title":"J Dtsch Dermatol Ges"},{"key":"5776_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1148660","volume":"10","author":"K Drenovska","year":"2023","unstructured":"Drenovska\u00a0K, Valeva\u00a0E, Shahid\u00a0M, Vassileva\u00a0S (2023) Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy. Front Med (Lausanne) 10:1148660","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"5776_CR77","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1111\/jdv.18907","volume":"37","author":"K Bakirtzi","year":"2023","unstructured":"Bakirtzi\u00a0K, Sotiriou\u00a0E, Papadimitriou\u00a0I, Vakirlis\u00a0E, Delli\u00a0FS, Ioannides\u00a0D (2023) Anti-interleukin-17A biologics for the long-term treatment of bullous pemphigoid: A prospective, cohort study. J\u00a0Eur Acad Dermatol Venereol 37(6):e749\u2013e751","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"5776_CR78","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.jcjo.2022.11.011","volume":"59","author":"M Lin","year":"2024","unstructured":"Lin\u00a0M, Boonsopon\u00a0S, Manhapra\u00a0A, Zhao\u00a0T, Foster\u00a0CS (2024) Elevated serum BAFF in patients with ocular cicatricial pemphigoid. Can J Ophthalmol 59(2):e105\u2013e110","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"5776_CR79","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard-2023-224691","volume":"83","author":"T Dorner","year":"2024","unstructured":"Dorner\u00a0T, Kaul\u00a0M, Szanto\u00a0A, Tseng\u00a0JC, Papas\u00a0AS, Pylvaenaeinen\u00a0I et\u00a0al (2024) Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis 83(3):360\u2013371","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5776_CR80","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/annrheumdis-2012-202775","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese\u00a0MC, Fleischmann\u00a0RM, Greenwald\u00a0M, Satterwhite\u00a0J, Veenhuizen\u00a0M, Xie\u00a0L et\u00a0al (2013) Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis 72(9):1461\u20131468","journal-title":"Ann Rheum Dis"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05776-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:03:48Z","timestamp":1790899428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05776-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5776"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05776-1","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0van Beek\n                      : A. Finanzielle Interessen: F\u00f6rderung der Universit\u00e4t zu L\u00fcbeck im Rahmen des L\u00fcbecker Advanced Clinician Scientist Programm. \u201eThe author Nina van Beek gratefully acknowledges support from the Detlef Zillikens Clinician Scientist Academy of Precision Health in Schleswig-Holstein (PHSH) and the Clinician Scientist Academy L\u00fcbeck.\u201d. \u2013 Fresenius Medical Care: Vortragshonorar und Reisekosten bei eingeladenem Vortrag, EADV: Reisekosten bei eingeladenem Vortrag, Euroimmun: Reisekosten bei eingeladenem Vortrag. \u2013 Erfinderin im Patent 2200F_EP4345775A1, US20240118209A1 und CN117805383A mit der FA Euroimmun. \u2013 B. Nichtfinanzielle Interessen: Angestellte \u00c4rztin Universit\u00e4tsklinikum Schleswig Holstein, Campus L\u00fcbeck | Mitgliedschaften: ADF, EADV, AGPD der DDG, TAsk Force AIBD der EADV.\n                      E.\u00a0Schmidt\n                      : A. Finanzielle Interessen: Forschungskooperationen mit Euroimmun, ArgenX, Dompe, Chugai, Almirall, Sanofi.\u00a0\u2013 Honorare und\/oder Kostenerstattung von ArgenX, AstraZeneca, Leo, Chugai, Almirall, Janssen, LoopBio, Sanofi, AbbVie, Biocryst.\u00a0\u2013 Berater: Chugai, ArgenX, Sanofi, LoopBio, Sanofi, Leo, Almirall.\u00a0\u2013 B. Nichtfinanzielle Interessen: Institutsdirektor, Universit\u00e4t zu L\u00fcbeck | Koordinator von Leitlinien zu bull\u00f6sen Autoimmundermatosen; Chair, EADV task force zu bull\u00f6sen Autoimmundermatosen.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}